Kelly Qiao

We are a global biotech company committed to developing new and effective therapies for psychiatric and neurological disorders affecting millions of patients in need.

Vivacta is a biotech company spun out from global leading investors, dedicated to advancing in vivo CAR-T therapies.

Rona Therapeutics is a pioneering nucleic acid therapeutics company to discover, develop and deliver transformative modular RNA medicines to treat patients globally. Rona Therapeutics is a global leader in nucleic acid innovative drug platform company, specializing in the treatment of metabolic diseases and neurological diseases. Rona Therapeutics is always committed to developing the best and first-in-class siRNA drugs with differentiation and innovation to address unmet needs and improve outcome in cardiovascular diseases, obesity, and MASH. In addition, Rona Therapeutics is unlocking potential of extra-hepatic delivery for neurological disorders and adipose/muscle delivery for various metabolic syndromes.

As a fast growing medtech company，We are focusing on endoscopic intervention therapy market and prioritize the development of single-use electronic endoscope product.

Intravascular Lithotripsy

Grit Bio is a Chinese cell therapy company founded in 2019. The company is developing tumor-infiltrating lymphocyte (TIL) therapy program to address the unmet medical needs and to improve the quality of life for patients with solid tumor. GT101 - Grit’s non-gene-modified TIL product manufactured using proprietary process - is the first TIL product received Investigational New Drug (IND) approval in China and is currently in Phase 1 clinical trial. Grit Bio has established three core technology platforms for its TIL development: StaViral® - a retroviral system tailored for TIL engineering, ImmuT Finder® - a high-throughput screening platforms identifying novel T-cell targets, and TIL expansion platform StemTexp® that preferentially enriches TCM and TSCM populations of TIL. The company is currently developing potentially best-in-class gene-engineered TIL therapy based on these platforms.

Aurora耀乘健康科技成立于2020年8月，我们专注于生命科学临床研发领域，并致力于开创全球领先的新一代临床研究SaaS平台，以云计算、大数据、AI及企业服务级B2B SaaS技术，来赋能生命科学研发的数据分析及运营管理，以加速原研药和新型医疗器械的商业化，造福人类健康！主创团队拥有丰富的产品及行业经验，均来自Google、Verily、Splunk、Medidata、Veeva等相关领域的全球领导企业。 美国公司网址：https://www.alphalifesci.com

ProfoundBio is now part of Genmab. As part of Genmab, we are looking forward to continuing our work of developing novel antibody-based therapeutics for patients with cancer. This page will no longer be active or monitored. For updates on our work, please follow Genmab at: https://bit.ly/3Kf80df.

Beijing Yuanxin Technology Group Co., Ltd("Yuanxin Technology") is a healthcare technology group dedicated to delivering value to patients. Established in 2015, the Beijing-based group now employs over 4,000 professionals. Yuanxin Technology’s business model focuses on patients’ whole medical service cycle. Yuanxin Technology features three pillar services, namely, out-of-hospital comprehensive patient service, supply side empowerment service and innovative healthcare service. All these services are committed to realizing one common goal of building a synergetic healthcare platform that provides comprehensive, personalized and considerate services to patients. With online and offline channels, Yuanxin integrates hospital and out-of-hospital resources and delivers integrated medical insurance solutions. By breaking the traditional boundary of medical services, pharmaceutical circulation, health insurance, and IT application in healthcare, it establishes a patient-centered digital course management system featuring extensive involvement of hospitals, physicians, pharmaceutical companies and insurers, so as to contribute to the sustainability of the healthcare industry.

上海镁信健康科技有限公司，自成立以来，坚持以智能科技为驱动，以医疗和保险双平台为核心，从聚焦创新支付到落脚创新型医疗健康服务，构建行业医药险新生态，全面覆盖社会各层次需求。从一枚行业新秀迅速晋升为一家领先的创新型医疗健康服务公司。 2017年，国内对全球罕见病药物和创新药物敞开“绿色通道”，但这些昂贵的新药不能被医保所覆盖，传统商业保险则出于利益考量不愿介入。捕捉到行业空白的镁信健康，应时而动，推出国内首个药品支付计划，有效连接起医疗行业和保险行业，解决谁给老百姓看病买单的难题。 2018年，镁信健康旗下“药康付”平台正式上线，引入药企、药房、商保公司各方，一方面帮助用户以更低价格获得好药，同时开发更多创新金融和服务产品满足用户更多需求。 为了尽快纾解天价进口“救命药”买不起的困境，镁信健康积极响应国家建立多层次医疗保障体系的号召，联合微保与泰康在线于2019年共同推出业内首个针对已患癌人群的抗癌保障产品 “药神保”，将国内已上市但未纳入社保目录的全部药品纳入保障，尤其是患者亟需的抗癌药和特效药。 2019年底起，镁信健康担任起“城市多层次保障体系搭建的综合解决方案提供方”角色，打造覆盖全人群的创新医疗解决方案，开始试水城市定制型商业补充医疗保险产品——“惠民保”。2020年，“惠民保”在各大城市陆续上线，投保门槛降低，不限年龄与职业，可以带病参保，真正帮助到需要保险的非健康人群，回归健康险的初衷，由此一跃成为老百姓热爱的“网红产品”。 镁信健康先后为“苏惠保”、“西湖益联保”、“惠衢保”、“沪惠保”、“北京普惠健康险”等多款产品提供专业的产品设计、药品服务和技术支持，累计覆盖北京、上海、杭州、宁波等40余座城市。这个由政府指导、商业保险公司承保的城市定制型普惠补充医疗保险产品，让老百姓实实在在获得了实惠。 公开数据显示，目前个人医疗卫生支出比例已经从新世纪初的60%左右下降到了30%以下，这得益于顶层设计与大健康产业链各方的努力。伴随政策东风，镁信健康也走出了自己的特色道路，被外界誉为“健康险的芯片公司”。 2020年11月，随着康付互联网医院获批执业，在海南博鳌乐城独立设置的首家互联网医院落地，镁信健康正式吹响战略升级号角，从聚焦医疗支付转变为全面患者服务，涉及领域包括互联网医院、MDT、商保直付、疗效保险、用药指导等。 四年间，镁信健康已获得多轮融资，中再集团、上海医药集团等各领域股东硬实力的加持，夯实镁信健康在创新医疗支付领域的竞争优势，也让镁信健康有信心走得更远。 未来，镁信健康将继续秉持“以患者为中心的医疗服务创新，助力构建更有幸福感的未来社会”的发展愿景，持续提升医疗服务能力，进而为百姓提供更全面、更经济、更优质的医疗健康服务。 站在第五年的起点上，镁信健康不忘“帮助平凡人”的初心，将继续升级平台化优势，全面推进场景化服务，从此前单纯针对病患个体，转化成服务每一个病患家庭，逐步建立跟踪式、保姆式的服务理念和行为，延展产品和服务边界，在互联网医疗数字化、产业化等领域持续拓展创新业务，继续赋能医疗健康产业链，为“健康中国2030”长远目标的实现贡献力量。未来，镁信健康将继续努力解决患者医疗支出负担，为百姓提供更全面、更经济、更优质的医疗健康服务，一起期待人人有保障，全家享健康的未来社会。

HiFiBiO Therapeutics is a clinical-stage global biotech pioneering a unique high-resolution translational solution (DIS®, Drug Intelligence Science) to enhance the probability of success for immunotherapies. DIS® combines unique single-cell capabilities with AI/ML approaches using patient samples to discover novel targets, effective antibody drugs, and predictive biomarkers. With DIS®, HiFiBiO gains an unprecedented understanding of immune modulation in human diseases driving a robust clinical pipeline of transformative immunotherapies. Additionally, HiFiBiO has partnered with major multinational pharmaceutical and biotech companies applying its innovative DIS® approach. HiFiBiO Therapeutics is headquartered in Cambridge, MA with additional operations in Paris, France, Hong Kong, Shanghai, and Hangzhou, China.

Insilico Medicine, a clinical stage biotech company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.

We are a global biotech company committed to developing new and effective therapies for psychiatric and neurological disorders affecting millions of patients in need.

Vivacta is a biotech company spun out from global leading investors, dedicated to advancing in vivo CAR-T therapies.

Rona Therapeutics is a pioneering nucleic acid therapeutics company to discover, develop and deliver transformative modular RNA medicines to treat patients globally. Rona Therapeutics is a global leader in nucleic acid innovative drug platform company, specializing in the treatment of metabolic diseases and neurological diseases. Rona Therapeutics is always committed to developing the best and first-in-class siRNA drugs with differentiation and innovation to address unmet needs and improve outcome in cardiovascular diseases, obesity, and MASH. In addition, Rona Therapeutics is unlocking potential of extra-hepatic delivery for neurological disorders and adipose/muscle delivery for various metabolic syndromes.

As a fast growing medtech company，We are focusing on endoscopic intervention therapy market and prioritize the development of single-use electronic endoscope product.

Intravascular Lithotripsy